Protagonist Therapeutics

Company snapshot

Protagonist Therapeutics (Nasdaq: PTGX) is a biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of p

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 33 US patent(s) indexed to this assignee profile.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Protagonist Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Protagonist Therapeutics.

1. Jun 8, 2026 Clinical update

   VERIFY — Phase 3

2. Jun 5, 2026 Clinical update

   PN-881 Oral Solution — Phase 1

3. Jun 5, 2026 Clinical update

   Placebo — Phase 3

4. May 23, 2026 Clinical update

   Open-label rusfertide — Phase 3

5. May 23, 2026 Clinical update

   PN-943 — Phase 2

View all clinical trial activity →

• What is Protagonist Therapeutics?

  Protagonist Therapeutics is a pharma organization headquartered in Newark, USA. It trades on NYSE under ticker PTGX. Primary therapeutic focus areas include Polycythemia Vera, Ulcerative Colitis Chronic Moderate, Celiac Disease, Ulcerative Colitis, Hereditary Hemochromatosis. Nov

• Is Protagonist Therapeutics publicly traded?

  Yes. Protagonist Therapeutics is listed with ticker PTGX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Protagonist Therapeutics develop or market?

  We link 5 drug profile(s) where Protagonist Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/protagonist-therapeutics-inc#company-drugs.

• What are the latest developments for Protagonist Therapeutics?

  In the last 12 months our linked public records show 13 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Protagonist Therapeutics focus on?

  Protagonist Therapeutics focuses on Polycythemia Vera, Ulcerative Colitis Chronic Moderate, Celiac Disease based on our analysis of their pipeline programs and drug development activities.